Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department

Emergency Medicine Australasia : EMA
Colin A Graham

Abstract

This paper critically reviews the major drug types that are currently used in the management of acute cardiogenic pulmonary oedema. As decompensated heart failure becomes an increasingly common problem in emergency departments in the developed world, optimization of emergency drug therapy for these critically ill patients is essential. The evidence base for 'routine therapy' in the ED is considered. The review also briefly considers emerging pharmacological therapies that may have an impact on future management of cardiogenic pulmonary oedema.

References

Jul 1, 1978·The American Journal of Medicine·J S Forrester, D D Waters
Jul 1, 1976·JACEP·N J DiamondJ W Elliot
Sep 7, 1992·The Medical Journal of Australia·J A Chambers, C J Baggoley
Jun 1, 1992·Annals of Emergency Medicine·R C Wuerz, S A Meador
Feb 1, 1972·Annals of Internal Medicine·A Aberman, M Fulop
Jan 1, 1995·The Journal of Emergency Medicine·R E FrommL R Gibbs
Mar 9, 1996·Lancet·D Northridge
Mar 1, 1996·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·J M Christenson
Mar 1, 1996·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·R J HamiltonE J Gallagher
Nov 1, 1996·Clinical Pharmacology and Therapeutics·M GrossmannB B Hoffman
Nov 5, 1997·Annals of Emergency Medicine·G BertiniG Gensini
Feb 28, 1998·Postgraduate Medicine·A D Sacchetti, R H Harris
Dec 23, 1998·British Journal of Clinical Pharmacology·F StankeG Bessard
Oct 26, 1999·The American Journal of Emergency Medicine·A SacchettiV Moyer
Jan 14, 2000·BMJ : British Medical Journal·G JacksonG Y Lip
Jan 29, 2000·BMJ : British Medical Journal·M K DaviesG Y Lip
Feb 25, 2000·BMJ : British Medical Journal·T MillaneG Y Lip
Feb 24, 2001·Clinical Therapeutics·E G Boyce, E M Umland
Apr 21, 2001·Lancet·G CotterI Shpirer
May 18, 2001·Current Opinion in Cardiology·G CotterZ Vered
May 17, 2002·Current Opinion in Cardiology·John G F Cleland, James McGowan
Aug 29, 2002·Journal of Cardiovascular Pharmacology·Masao Endoh
Dec 19, 2002·Drugs·Gillian M Keating, Karen L Goa
May 2, 2003·The New England Journal of Medicine·Umesh N KhotGary S Francis
May 9, 2003·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Diane Tran, Laurence Guy Howes
Jun 5, 2003·Postgraduate Medical Journal·L K M De Bruyne

❮ Previous
Next ❯

Citations

Jun 1, 2010·QJM : Monthly Journal of the Association of Physicians·A GrayS Tilley
Apr 13, 2015·Revista Española De Cardiología·Pablo Herrero-PuenteUNKNOWN members of the ICA-SEMES group
Mar 31, 2005·Emergency Medicine Australasia : EMA·Peter Cameron, Henry Krum

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.